Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Other solid neoplasm 2Gynecologic 2

Conditions

Ovarian Neoplasms 3Mesothelioma 3Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 2Mesothelioma, Malignant 2Severe combined immunodeficiency with sensitivity to ionizing radiation 1Carcinoma, Pancreatic Ductal 1

Interventions

Cyclophosphamide 6pembrolizumab 5fludarabine 4fludarabine phosphate 2amatuximab 2SS1(dsFv)PE38 2tocilizumab 1sotorasib 1sargramostim 1enzalutamide 1entinostat 1defactinib 1bemcentinib 1aldesleukin 1alanosine 1Tablets 1Sorafenib 1Sirolimus 1Quality of Life 1Polymerase Chain Reaction 1Pentostatin 1Pemetrexed 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Microarray Analysis 1Ipilimumab 1Interleukin-12 Subunit p35 1Interferon-gamma 1Interferon-alpha 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × amatuximab × Other solid neoplasm × Clear all
NCT01521325 2016-09-30

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

Morphotek

Phase 1 Completed
6 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT00325494 2014-07-17

A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer

Morphotek

Phase 1 Completed
24 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡